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Abstract
Background: Gene expression technologies have the ability to generate vast amounts of data, yet
there often resides only limited resources for subsequent validation studies. This necessitates the
ability to perform sorting and prioritization of the output data. Previously described methodologies
have used functional pathways or transcriptional regulatory grouping to sort genes for further
study. In this paper we demonstrate a comparative genomics based method to leverage data from
animal models to prioritize genes for validation. This approach allows one to develop a disease-
based focus for the prioritization of gene data, a process that is essential for systems that lack
significant functional pathway data yet have defined animal models. This method is made possible
through the use of highly controlled spotted cDNA slide production and the use of comparative
bioinformatics databases without the use of cross-species slide hybridizations.
Results: Using gene expression profiling we have demonstrated a similar whole transcriptome
gene expression patterns in prostate cancer cells from human and rat prostate cancer cell lines
both at baseline expression levels and after treatment with physiologic concentrations of the
proposed chemopreventive agent Selenium. Using both the human PC3 and rat PAII prostate
cancer cell lines have gone on to identify a subset of one hundred and fifty-four genes that
demonstrate a similar level of differential expression to Selenium treatment in both species. Further
analysis and data mining for two genes, the Insulin like Growth Factor Binding protein 3, and
Retinoic X Receptor alpha, demonstrates an association with prostate cancer, functional pathway
links, and protein-protein interactions that make these genes prime candidates for explaining the
mechanism of Selenium's chemopreventive effect in prostate cancer. These genes are subsequently
validated by western blots showing Selenium based induction and using tissue microarrays to
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demonstrate a significant association between downregulated protein expression and
tumorigenesis, a process that is the reverse of what is seen in the presence of Selenium.
Conclusions: Thus the outlined process demonstrates similar baseline and selenium induced gene
expression profiles between rat and human prostate cancers, and provides a method for identifying
testable functional pathways for the action of Selenium's chemopreventive properties in prostate
cancer.
Background
Gene expression profiling, along with other methods to
evaluate the global changes in genomes, provides the
opportunity to understand whole scale changes present in
human biology. Yet the sheer mass of data presented by
these techniques often makes subsequent analysis diffi-
cult. Techniques such as gene expression profiling may
result in the identification of hundreds if not thousands of
differentially expressed genes that may be associated with
the biological process, but may also represent noise
related to the biological and technical variation. In an eco-
nomic environment where limited resources are available
for the follow-up and validation of potential target genes
methods must be provided for the prioritization and sort-
ing of data. Previous methods have relied heavily on the
mapping of metabolic pathways or transcription factor
binding sites [1-5]. These processes rely on the premise
that the metabolic pathways associated with a given dis-
ease are well delineated, or that groups of proteins with
very similar structural or functional design are involved in
the disease process. In situations where these assumptions
may not be true, alternative methods for the sorting of the
data are needed. Here we demonstrate an alternative
approach using comparative genomics and animal mod-
els of human prostate cancer to sort and identify genes
involved in the response of prostate cancer cells to the
proposed chemopreventive agent Selenium [6,7]. This
process takes advantage of the continued sequencing of
multiple animal genomes and the ability to produce gene
expression profiles in multiple species. Through the use of
these techniques one can leverage established animal
models to identify genes associated with human disease
processes, as is demonstrated here with the identification
of Insulin-like growth factor-2 Binding protein 3
(IGFBP3) and retinoid-X-receptor alpha (RXRalpha).
Results
Generation of common genes and homologs
Sequence validated gene libraries for both the rat and
human DNAs were obtained from Research Genetics
(Huntsville, AL), and were supplemented with additional
DNA samples obtained from the University of Iowa rat
clone sequencing program [8]. The majority of the rat
DNAs, and a subset of the human DNAs were resequenced
by Dr. J. Quackenbush at TIGR through a joint Program in
Genomic Applications consortium. The GeneBank acces-
sion numbers for the 19,200 individual human or rat
clones present in the recent slide printings were used to
query the NCBI Unigene database to return the associated
Unigene IDs. Unigene IDs were returned for virtually all
identified clones, and were placed in an Oracle database
where they were compared with the downloaded NCBI
Homologene dataset (build 106) of rat, mouse, and
human homologues. Of the 19,200 clones, 5740 genes
were identified with homologues present on both the rat
and human slides. This homologue set was used for the
subsequent comparisons across species.
Similar global and prostate gene expression profiles 
between rat and human prostate cancer cell lines
We have sought to compare the rat and human prostate
cancer transcriptomes in an effort to judge the degree of
similarity between the two cell types. Because the use of
differentially expressed genes would bias the comparison
by eliminating the majority of genes that do not show any
difference, we used the absolute level of expression for
each gene and compared the rat and human genes for sig-
nificant differences in absolute expression levels. In order
to derive the absolute level of expression for individual
genes in human or rat prostate cancer cells we used expres-
sion values derived from the associated self-self
hybridizations performed for each cell line. The experi-
ments were facilitated by the use of slides that have been
quality controlled for the quantity of spotted target DNA
through the use of a FITC label third dye [9]. These slides
were subsequently imaged for FITC fluorescence and
sorted based on the similar amounts of target DNA
present on each slide [10]. Using the third dye quality
control correlation coefficients of greater than 0.80 are
routinely achieved between slide replicates [9]. In this
manner comparisons of bound hybridized probe can be
made across slides with a degree of confidence. RNA sam-
ples from cells were harvested, labeled, and homotypi-
cally hybridized to establish the baseline level of
consistency within the hybridizations. Performing slice
analysis on the normalized homotypic gene expression
data across all the self-self hybridization slides within a
species and retaining genes that demonstrated consistent
expression patterns within two standard deviations of the
mean expression value was performed to remove a degree
of error from the technical replicates. Using the third dye
as a baseline for comparison, these common expressedBMC Genomics 2004, 5:58 http://www.biomedcentral.com/1471-2164/5/58
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genes were then broken down into their component Cy3
or Cy5 expression vectors and used to build the transcrip-
tomes for each gene using their absolute expression val-
ues. These transcriptomes were then used to compare
expression values between the rat and human cell lines.
These genes were annotated and gene homologues identi-
fied from the NCBI Homologene[11] dataset of rat-
human homologues. Thus from a dataset of 5740 homo-
logues, 2883 genes were found that were present within
this experimental dataset and expressed in both the rat
and human prostate cancer cell lines, and thus could be
used for comparative genomics. These samples were proc-
essed using the Multiexperiment Viewer mircoarray statis-
tical analysis and visualization program developed by
TIGR [12]. Files were loaded and visualized for compari-
son across the 2883 common expressed genes in a self-
organizing tree algorhythm [13] (figure 1) and analyzed
for similarities in global expression patterns. The hierar-
chical clustering in self-organizing trees failed to demon-
strate a pattern of clustering between species. T-test
analysis [12,14] between the human and rat cell lines
identified 58 genes (2%) which demonstrated signifi-
cantly different expression patterns between species (p <
0.01 with Bonferroni correction). Thus in these compari-
sons, 2826 genes, or 98% of the genes examined, failed to
demonstrate a statistically significant difference in expres-
sion between the human and rat prostate cancer cell lines.
Using principle components analysis (figure 2, [12]) these
studies can be visualized, and demonstrate while there is
some clustering of the rat and human prostate cancer cell
lines, the differences are not significant. Thus when com-
paring gene expression patterns in rat and human cell
lines one will detect significant species-specific differences
in expression in 1 out of every 50 genes, with the majority
of the genes demonstrating similar expression patterns.
The presence of a large quantity of genes whose expression
may be related to general cellular functions, as opposed to
prostate specific metabolism, could infuse a significant
amount of homogeneity to the data. In the presence of
such homogeneity it may be impossible to identify the
true differences that are related to prostate cellular func-
tion, and thus the perceived similarities may be artifac-
tual. To address this issue we sought to repeat the analysis
using only prostate related genes. To generate a list of such
genes we used cDNAs in eight normal human prostate
cDNA libraries present in the NCI Cancer Genome Anat-
omy Project [15]. Generation of a list of common genes
proved impossible, as the combination of more than four
of the cDNA lists resulted in the number of common
genes being reduced to zero. A similar result was obtained
when one attempted to generate a list of commonly
expressed genes across multiple different cancer cDNA
libraries. As an alternative approach we developed a list of
12,008 expressed genes were identified based on their
presence in at least one of the eight normal human
prostate cDNA libraries. The human Unigene IDs for each
of the expressed genes were then used to identify the
associated rat homologues from Homologene [11] and
yielded 2,269 homologous rat genes (18.9%), of which
1,319 (58.1%) had associated prostate cancer gene expres-
sion data. These 1,319 prostate expressed genes were then
used to repeat the comparative genomics. Similar visual
and clustering results were identified for the prostate tran-
scriptomes. T-test analysis [12,14] between the human
and rat cell lines identified 30 prostate expressed genes
(2%) which demonstrated significant differential expres-
sion between species (p < 0.01 with Bonferroni correc-
tion, while 1,289 genes (98%) failed to demonstrate a
significant difference in expression across species. Thus
even when only prostate expressed genes are considered,
similar results were obtained. Between the rat and human
prostate cancer cell lines the patterns of expression are
similar for 49 of 50 genes examined.
Comparison of global and prostate specific differential 
gene expression profiles between rat and human prostate 
cancer cell lines treated with selenium
While global gene expression profiles appear to be similar
between rat and human prostate cancer cell lines one
wonders whether the response to specific physiologic
stimuli may elicit similar transcriptional changes. If so,
one may be able to infer a degree of homology in their
biological response to the stimuli. This has already been
observed on a physiological level for the rat models of
prostate cancer. For example, rat and human prostate can-
cers respond very similarly to chemotheraputic and envi-
ronmental agents including hormonal agents (both
respond), cyclophosphamide (neither respond), high fat
diets (increased incidence), and soy isoflavones
(decreased incidence) [16-22]. In an effort to evaluate
these similar biological responses we have compared the
transcriptomes between rat and human prostate cancer
cell lines treated with the proposed prostate cancer chem-
opreventive agent Selenium. Samples from the human
PC3 and rat PA-III cell lines were treated with Selenium
and examined for differential gene expression profiling.
These two cell lines were chosen based on their similar
biologic characteristics, as both cell lines were derived
from androgen independent metastatic tumors, and thus
represent tumors with similar biologic potential [23,24].
The cells were treated with twenty-five micromolar Sele-
nium for either 6 hours or 5 days, to identify both imme-
diate changes in gene transcription or changes related to
the long term exposure to Selenium. Due to our interest in
prostate cancer we have attempted to choose a form and
concentration of Selenium that would be reflected in the
ongoing prevention trials such as the SELECT prostate
cancer prevention trial [25,26]. In this trial patients
receive Selenium in the form of Selenized baker's yeast.BMC Genomics 2004, 5:58 http://www.biomedcentral.com/1471-2164/5/58
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Previous HPLC and electrospray mass spectroscopy stud-
ies have demonstrated that 85% of the Selenium in yeast
is present as selenomethionine [27]. Selenomethionine
has previously been used in in-vitro studies of prostate
cancer cells[28,29]. These studies demonstrated an inhibi-
tion of prostate cancer cell proliferation over a broad
range of concentrations, while an IC50 and/or decreased
expression was seen at concentrations above 70 micromo-
lar selenomethionine. To avoid the general effects of cell
inhibition or cell death while focusing on the effect of
Selenium we chose a lower concentration of 25 micromo-
lar selenomethionine. These changes, while not resulting
in increased cell death, did cause decreased cell division
and increased doubling time in both species (data not
shown). Common rat and human homologous genes
demonstrating differential expression by greater than two
standard deviations were identified and included 1123
genes after 6 hours and 1053 genes after 5 days of expo-
sure to Selenium. When the expression patterns of these
genes were compared across species by T-test and
principle component analysis as outlined above 713
genes (25%) were found to have statistically significant
differences in expression between species (p < 0.01 with
Bonferroni correction). Thus when comparing rat and
human samples, while the majority of the gene expression
changes are similar, in at least one in four genes (p = 0.75)
one can detect significant species specific differences in
expression alteration when cells are treated with Sele-
nium. Yet similar physiologic changes (decreased cellular
proliferation, increased cell death) were observed in both
species. These changes represent the desired physiologic
changes one would expect for the chemopreventive effects
of Selenium, and could be dissected by examining the
common transcriptional changes seen in both species
with respect to Selenium.
Combined differential expression patterns for selenium 
responsive genes identify common gene pathways
Because some of the differences in the rat and human
prostate cancer cell line transcriptomes may be related to
confounding variables such as culture methods, cell pas-
sage number, or time in culture, an effort was made to
focus on genes that are common, and as such may define
the similar Selenium based cell proliferative changes. The
subsets of 1123 and 1053 differentially expressed genes (6
hours and 5 days respectively) were analyzed for genes
that demonstrate similar changes in expression with
respect to Selenium across species. Of these differentially
expressed genes, 291 and 309 demonstrated up-regula-
tion in rat and human cells at 6 hours and 5 days respec-
tively. Likewise, 261 (6 hours) and 216 (5 days)
demonstrated down-regulation in the presence of Sele-
nium. When these subsets were further analyzed to iden-
tify genes with similar levels of up or down-regulation
(defined as ratio differences within 0.2 units of each
other) 81 genes were identified at 6 hours and 73 at 5 days
(table 1-see additional file 1). These genes included 40
ESTs or genes with limited associated data, and 90 defined
genes with associated gene data. Twenty-four of the genes
were common to Selenium treatment at both 6 hours and
5 days. Additional information related to these genes was
obtained using the GeneInfo data mining tool. This tool
was developed by the authors (MWD, XW, HL, GZ) to
allow for the rapid identification of supplemental data
from the biomedical literature related to genes of interest.
In brief, the tool allows one to cut and paste a list of genes
based on either Unigene or Genebank IDs and search
PubMed for associated references based on annotations of
the associated gene names. Additional search terms can be
stipulated by the user based on their knowledge of the
biological process or in response to results received from
the previous search. Results are returned in a table that
lists the number of references that met the search criteria
and provides a hyperlink to the associated references for
either downloading or viewing. In this way the user is
allowed to direct queries in an open manner based on
their own experience or unpublished data. In this manner
searches were conducted using the list of genes and the
search terms "prostate cancer", "Selenium", and "apopto-
sis" (table 1-see additional file 1).
IGFBP3 and RXR-alpha are expressed in the prostate, 
induced by selenium, and downregulated in prostate 
cancer
Of the 154 genes identified with similar cross-species dif-
ferential expression changes with respect to Selenium, two
genes were identified that had unique features based on
their associated references and interrelated functions.
These genes, IGFBP3 and RXR-alpha were both up-regu-
Gene expression profiles for human and rat prostate cancer  cells Figure 1
Gene expression profiles for human and rat prostate cancer 
cells. Clustering of the expressed genes in the human 
(LNCAP, DU145, PRO4, LN4, and PC3 derivatives) and rat 
(AT3, MatLyLu, and PAIII) prostate cancer cell lines based on 
the common homologs as defined within to NCBI Homolo-
gene database. Raw data files are available for review from 
the corresponding author.BMC Genomics 2004, 5:58 http://www.biomedcentral.com/1471-2164/5/58
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lated with respect to Selenium and could be used to sug-
gest a model for Selenium action in prostate cancer. PXR-
alpha is upregulated in both rat and human prostate can-
cer cells at 5 days in response to Selenium. Likewise,
IGFBP3 is upregulated after six hours of Selenium treat-
ment in both species. These two genes both contained
Medline references with respect to prostate cancer, but
had not yet been implicated in Selenium action. Western
blotting performed on the human prostate cancer cell line
PC3 with respect to Selenium validated the bioinformati-
cally identified expression data (figure 3). To confirm the
role of these two proteins in the prostate immunohisto-
chemical studies on prostate cancer tissue microarrays
were performed to identify IGFBP3 and RXR-alpha in
both normal, nodular hyperplasia (benign prostatic
hypertrophy), high grade prostatic intraepithelial neopla-
sia (HGPIN), invasive carcinoma, and metastatic prostatic
carcinoma (table 1). These studies demonstrate that both
IGFBP3 and RXR-alpha are expressed in the normal
human prostatic epithelium (figure 4, table 1). IGFBP3 is
also expressed in the prostatic basal cells. Patterns of
expression were predominantly nuclear, a finding that has
been described for both proteins [30]. In addition, stain-
ing for IGFBP3 was also noted in the prostatic stroma,
consistent with IGFBP3's associated function as a secreted
protein. Decreased levels of IGFBP3 was noted in prostatic
cancers when compared to normal prostate epithelium (p
= 0.0044). Along with this decreased expression there was
a distinct shift in the protein localization nuclear to cyto-
plasmic was observed (p < 0.00001), and in cases where
expression was still present, there were decreased num-
bers and intensity of cell staining. IGFBP3 expression was
similar in HGPIN, invasive carcinoma, and metastatic car-
cinoma. The level and pattern of IGFBP3 expression in
nodular hyperplasia was similar to that seen in normal
prostate tissues, and significantly different from the
expression seen in cancer samples (p = 0.0036 and p <
0.00001 respectively). RXR-alpha expression was also sig-
nificantly downregulated in prostate cancer when com-
pared to normal prostate epithelium or nodular
hyperplasia (p < 0.0001), and was similar to that seen in
HGPIN and metastatic carcinoma. RXR-alpha expression
was consistently nuclear in the samples studied, and while
the intensity of staining was similar, in the remaining pos-
itive cancer cases there were decreased numbers of cells
staining (8.6 +/- 12.6% in malignant epithelium vs 20.0
+/- 25.5% in normal epithelium).
Principal Components Analysis of Rat and Human Prostate  Cancer Cell Lines Figure 2
Principal Components Analysis of Rat and Human Prostate 
Cancer Cell Lines. There is a clustering of the human (Pro4-
purple, LN4-dark-blue, PC3S-light blue, PC3US-yellow) and 
rat (MatLyLu-red, AT3-magenta, PAIII-green) prostate can-
cer cell lines in the same quadrant. The degree of separation 
within the quadrant was not significant by T-testing. Each 
sample is presented in duplicate based on independent Cy3 
and Cy5 vector profiles.
Expression of IGFBP3 and RXR-alpha with respect to  Selenium Figure 3
Expression of IGFBP3 and RXR-alpha with respect to Sele-
nium. Western blotting reveals an induction of RXR-alpha or 
IGFBP-3 protein after Selenium treatment of human PC3 
prostate cancer cells (arrows, upper row). Western blotting 
of immunoprecipitations from rat PAIII cells (bottom row) 
reveal RXR-alpha in immunoprecipitated IGFBP3 extracts 
(right panel) and IGFBP-3 in immunoprecipitated RXR-alpha 
extracts confirming and extending the reported interactions 
between the human proteins[40].BMC Genomics 2004, 5:58 http://www.biomedcentral.com/1471-2164/5/58
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Discussion
Leveraging cross-species bioinformatics in the 
prioritization of gene data
Through the use of cross-species comparisons of the
number of differentially expressed genes to be examined
after 6 hours and 5 days of Selenium treatment was
dropped from 9453 and 7768 to 1123 and 1053
respectively, an 87–89 percent reduction of the sample
size. Even with the use of multiple timepoints, the
number of differentially expressed genes was only reduced
in a single species study to 5934, less than half. By using
comparative genomics the final dataset was reduced to
154 genes, providing a greater than 100 fold enrichment
of the data. Thus by leveraging the additional biological
species the ability to reduce the final analysis pool was
substantial. This process only works if the species used
have biological relevance to the disease in question. The
choice of rat prostate cancer cell lines was made based on
their use as an animal model for the study of prostate can-
cer [31]. The animal systems have been extensively used in
the study of hormonal carcinogenesis, and in particular
have been of value as a model of environmental and die-
tary effects on prostate cancer [18-20]. Previous studies
have identified similar effects of rat animal models and
prostate cancer cell lines to soy based diets [17-19], high
fat diets [20-22], hormonal chemotherapeutics (Pollard,
personal communication) and standard chemotherapy
[32,33]. While comparative gene expression profiling has
been performed, this has usually been through cross-spe-
cies hybridizations to leverage RNA studies in species
where sufficient expressed transcripts in a given species
have not been identified for the production of species-spe-
cific gene expression slides, in particular for microbial
genomes [34-37]. Thus the approach taken here leverages
the production of species-specific gene expression profiles
along with the increasing amount of gene homolog data
generated by the sequencing of additional animal
genomes. It is expected that with future genome efforts
additional cross-species studies will be possible that lever-
age the knowledge of additional animal models in the
study of disease.
Similarities in prostate cancer transcriptomes across 
species
For both overall and prostate expressed genes, we have
failed to identify a significant difference in the transcrip-
tomes between rat and human prostate cancer cell lines.
This general similarity in transcriptomes may be due to
the inherent biological similarities of the cell lines and/or
their underlying biological origin. While the studies
sought to utilize prostate cancer cell lines with similar bio-
logical potentials (established cell lines all derived from
metastases) the degree of diversity present within the sam-
ples may account for some of the residual differences still
identified. In addition, the extended period of time that
these cell lines have been used has allowed for the
continued in-vitro evolution of the cells, and could possi-
bly extend those genomic differences. Yet the common
clustering of the rat and human cell lines together suggests
there are still significant similarities in their biological
potential. This is also demonstrated by the similar biolog-
ical potential of the cell lines when treated with a given
Table 2: Expression of IGFBP3 and RXRalpha in Prostatic Epithelium
Normal Prostate Nodular Hyperplasia HGPIN Prostate Cancer Metastatic Cancer
IGFBP3
Positive cases 105 62 49 202 25
Negative cases 5 1 9 36 8
Statistics (comparison) p = 0.0036 (cancer) N.S. (cancer) p = 0.0044 (normal) N.S. (cancer)
IGFBP3
Intensity (avg+/-std) 2.47 +/- 0.70 2.49 +/- 0.65 2.57 +/- 0.82 2.74 +/- 0.56 2.79 +/- 0.49
Percentage cells (avg+/- std) 8.3 +/- 13.5 7.5 +/- 12.5 8.8 +/- 15.2 4.4 +/- 6.6 8.5 +/- 12.6
Nuclear cases 92 59 40 94 8
Cytoplasmic cases 22 6 18 152 11
Statistics (comparison) p < 0.00001 (cancer) p = 0.065 (cancer) p < 0.00001 (normal) N.S. (cancer)
RXRalpha
Positive cases 92 58 35 112 16
Negative cases 10 3 31 125 19
Statistics (comparison) p < 0.00001 (cancer) N.S. (cancer) p < 0.00001 (normal) N.S. (cancer)
RXRalpha
Intensity (avg+/-std) 2.73 +/- 0.51 2.78 +/- 0.50 2.83 +/- 0.38 2.76 +/- 0.49 3 +/- 0
Percentage cells (avg+/- std) 20.0 +/- 25.5 23.2 +/- 25.7 8.4 +/- 12.5 8.6 +/- 12.6 4.2 +/- 4.6
Nuclear cases 92 58 35 107 16
Cytoplasmic cases 2 0 6 9 0
Statistics (comparison) N.S. (cancer) N.S. (cancer) N.S. (normal) N.S. (cancer)BMC Genomics 2004, 5:58 http://www.biomedcentral.com/1471-2164/5/58
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stimulus, in this example Selenium. This parallels the sim-
ilar physiological properties observed in the rat models of
human prostate cancer. Based on these features we dem-
onstrate that it is possible to identify functionally signifi-
cant genes related to Selenium response by using
comparative genomics. These findings also support the
use of animal models in the study of human prostate can-
cer by suggesting that there is enough inherent genomic
similarity that valuable insights may be gained from ani-
mal systems.
Comparative genomics identifies functionally significant 
genes with respect to selenium chemoprevention
A true test of the profiling method is the identification of
genes that have a functional significance to the experi-
mental system. In this case we have identified a series of
genes, which when examined with additional data mining
techniques, identifies genes with associated roles related
to apoptosis (IGFBP3, RXRalpha, dynamin-2), antioxi-
dant protection (selenoprotein N, peroxiredoxin I, zinc
metalloprotease, glutathione S transferase), cell cycle
(CDC26-anaphase promoting complex, kinetochore asso-
ciated protein), and protein balance (proteasome subunit
beta-4, ubiquitin conjugating enzyme). In addition, the
Expression of IGFBP3 and RXRalpha in human prostate tissues Figure 4
Expression of IGFBP3 and RXRalpha in human prostate tissues. Immunohistochemical staining for IGFBP3 is present as brown 
staining in normal prostate (A) and prostate cancer (C). Similarly RXRalpha expression is present in normal prostate (B) and 
lost in prostate cancer (D). All images recorded at 100× magnification.BMC Genomics 2004, 5:58 http://www.biomedcentral.com/1471-2164/5/58
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ability to sort the identified genes by their associated bio-
medical literature allowed the focus to shift to IGFBP3
and RXRalpha. Retinoids, through the retinoid X receptor,
have been shown to induce the expression of IGFBP3
[38]. In concert these two proteins act to induce apoptosis
in cancer cell lines [39]. In particular, recent data has
shown that these proteins work in synergy to enhance
apoptosis in prostate cancer, and that there is a physical
interaction between these two proteins in prostate cancer
cells[40]. Further validation and confirmatory data is pre-
sented here that demonstrates the selenium induced
expression and interaction between both RXRalpha and
IGFBP3 in prostate cancer cells, along with their expres-
sion in normal prostate epithelium and subsequent
down-regulation in malignant prostatic epithelium. This
allows one to pose a model by which the restoration of
IGFBP3 and RXRalpha levels by Selenium treatment may
lead to the disruption of prostate tumorigenesis. This
model is testable, and if validated, would present not only
a mechanism by which Selenium may exert its effect, but
provide a biomarker for assaying the effect of Selenium
supplementation in the ongoing prostate cancer preven-
tion clinical trials.
Conclusions
Using gene profiling on highly controlled spotted cDNA
arrays we have demonstrated that similar baseline and
selenium induced gene expression profiles can be identi-
fied between rat and human prostate cancer cells. This has
allowed us to filter our gene expression data to identify
genes whose transcriptional response to Selenium is sim-
ilar across species, and by so doing focus our discovery
process on specific common physiologic pathways. Two
such proteins, RXR-alpha and IGFBP-3, which may be
located in a common pathway, have been identified as
dysregulated in human prostate cancers. This provides fur-
ther support that the cross-species methods employed
here can identify genes with roles in human prostate
cancer.
Methods
Cell culture and selenium treatment
Cell lines were received from ATCC, Rockford, MD,
(LNCap, DU-145, MatLyLu, AT3), from Drs. Paul Lind-
holm and Andre Kadjacsy-Balla (LN4, Pro4, PC3, PC3-
NI(PC3US), PC3-I(PC3-S)), or Dr. Morris Pollard and
Mark Suckow (PA-III). These cells were cultured in RPMI
(DU-145) or DME medium supplemented with 10% fetal
calf serum, 10 mM glutamine, and 10 mM sodium pyru-
vate, and passaged 1:8 or 1:10 when the cells reached 70–
80% confluence with trypsin-EDTA. For the Selenium
studies PC3 or PAIII cells from a single cell stock were
seeded at 1 × 10EE4 cells per ml and grown to 50% con-
fluence at which time the culture medium was changed to
either standard growth medium (above) or medium sup-
plemented with twenty-five micromolar Selenium
(Seleno-DL-methionine, Sigma cat# S3875, St. Louis
MO). The cells were then cultured for an additional 6
hours or 5 days. Cells that reached 80% confluence prior
to the five day timepoint were split using trypsin-EDTA
and replated in either control or selenium-containing
medium for the duration of the experiment. Cells were
monitored for viability and cell growth with parallel
growth curves conducted in triplicate, this data
demonstrated the previously described [41,42] decrease
in cellular proliferation (data not shown) observed in the
presence of Selenium.
RNA isolation and quantitation
RNA was isolated from cells using Trizol (Invitrogen cat #
15596018, Carlsbad, CA) and subsequently examined for
quality using agarose gel electrophoresis and Gelstar
nucleic acid stain against known RNA standards and
failed to demonstrate significant degradation based on
the presence of high molecular weight RNA species, and
intact 28s and 18s ribosomal RNA bands.
DNA library preparation and amplification
Sequence-verified rat and human libraries (Research
Genetics, Huntsville, AL, and University of Iowa cDNA
clone set, IA), consisting of 41,472 human clones and
36,000 rat clones were used as a source of probe DNA. A
subset of 200 randomly selected clones were chosen from
these libraries, resequenced locally, and demonstrated
clone accuracy of 92%. We have opted to reformat librar-
ies from 96 to 384-format for culture growth/archiving,
PCR, purification, and printing. This has reduced the
number of plates of our 41,472 human clone library from
432 to a more manageable 108, and the rat clone library
from 375 to 94. The library was reformatted and subse-
quently manipulated using slot pin replicator tools (VP
Scientific, San Diego, CA). Cultures were grown in 150 ul
Terrific Broth (Sigma, St. Louis, MO) supplemented with
100 mg/ml ampicillin in 384 deep-well plates (Matrix
Technologies, Hudson, NH) sealed with air pore tape
sheets (Qiagen, Valencia, CA) and incubated with shaking
for 14–16 hr. Clone inserts were amplified in duplicate in
384-well format from 0.5 µl bacterial culture diluted 1:8
in sterile distilled water or from 0.5 µl purified plasmid
(controls only) using 0.26 µM of each vector primer
{SK865 5'-fluorescein-GTC CGT ATG TTG TGT GGA A-3'
and SK536: 5'-fluorescein-GCG AAA GGG GGA TGT GCT
G-3'} (Integrated DNA Technologies, Coralville, IA) in a
20 µl reaction consisting of 10 mM Tris-HCl pH8.3, 3.0
mM MgCl2, 50 mM KCl, 0.2 mM each dNTP (Amersham,
Piscataway, NJ), 1 M betaine, and 0.50 U Taq polymerase
(Roche, Indianapolis IN). Reactions were amplified with
a touchdown thermal profile consisting of 94°C for 5
min; 20 cycles of 94°C for 1 min, 60°C for 1 min (minus
0.5° per cycle), 72°C for 1 min; and 15 cycles of 94°C forBMC Genomics 2004, 5:58 http://www.biomedcentral.com/1471-2164/5/58
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5 min; 20 cycles 94°C for 1 min, 55°C for 1 min, 72°C
for 1 min; terminated with a 7 min hold at 72°. PCR reac-
tions analyzed for single products by 1% agarose gel elec-
trophoresis analysis. Products from replicate plates were
pooled and then purified by size exclusion filtration using
the Multiscreen 384 PCR filter plates (Millipore, Bedford,
MA) to remove unincorporated primer and PCR reaction
components. Forty wells of each 384-well probe plate
were quantified by the PicoGreen assay (Molecular
Probes, Eugene, OR) according to the manufacturers
instructions. After quantification, all plates were dried
down, and reconstituted at 150 ng/µl in 3% DMSO/1.5 M
betaine.
Array slide fabrication
A single printing array containing 19,200 elements
(human) or 2 arrays of 9,600 (rat), were printed on poly-
L-lysine coated slides prepared in-house (1–2 arrays/
slide) as previously described [9]. Printing was conducted
with a GeneMachines Omni Grid printer (San Carlos, CA)
with 16 or 32 Telechem International SMP3 pins (Sunny-
vale, CA) at 40% humidity and 22°C. To control pin
contact force and duration, the instrument was set with
the following Z motion parameters, velocity: 7 cm/sec,
acceleration: 100 cm/sec2, deceleration: 100 cm/sec2. All
slides were post-processed using the previously described
nonaqueous protocol[9]. Slide coating was performed as
described previously [43]. Image files on all arrays were
collected after blocking (fluorescein), and again after
hybridization (Cy3 and Cy5) with a ScanArray 5000 (GSI
Lumonics, Billerica, MA).
Experimental design and bioinformatics based data 
analysis
The experimental design utilized two biological replicates
for each comparison with each replicate incorporating a
Cy3/Cy5 dye flip. In addition, self-self hybridizations
were performed for each sample to ensure experimental
accuracy and evaluate expression bias. Comparisons were
organized in a loop design for either human or rat pros-
tate cancer cell lines, or were run as two-sample compari-
sons of baseline untreated control and Selenium treated
cells. Array image TIFF files were analyzed with Gleams
software (Nutec Sciences, Atlanta, GA). Additional TIFF
file analysis, data normalization, clustering, and principle
components analysis was performed using the Spotfinder,
MIDAS and MultiExperiment Viewer Software from The
Institute for Genomic Research (TIGR, Rockville, MD,
[44], [12]) and used default values set in the MCW
Practical Guide to TIGR Software Use (M. Datta, unpub-
lished). In brief, image expression data was used as chan-
nel intensity minus background and intensity thresholds
were set at a value of 300. Images were analyzed as dye flip
pairs normalized using MIDAS with LocFit based LOW-
ESS normalization and slice analysis set at two standard
deviation cutoffs and a sample data population of 500
[45]. Samples were then averaged across two dye flip rep-
licate pairs with removal of zero/dropped values using
locally developed averaging software from the BEAR
microarray suite (M. Datta, submitted). These final aver-
aged values were subsequently annotated using the BEAR
suite annotator and used for pattern identification and
correlation with gene homologs. Homologous genes were
identified from the NCBI homologene database ftp files
ftp://ftp.ncbi.nih.gov/pub/HomoloGene/ and parsed
using local scripts and databases present in the Bioinfor-
matics Program,[46]. Additional data mining to identify
references in the biomedical literature associated with spe-
cific genes and user chosen search terms was performed
using the locally developed GeneInfo data tool (M. Datta,
submitted). Raw data files, along with analyzed data sub-
sets are available for use and study and can be obtained
via a secure ftp site after contacting the corresponding
author mdatta@mcw.edu.
Protein purification, western blotting, and 
immunoprecipitation
Protein extracts were prepared and immunoprecipitations
and/or western blots made from five day twenty-five
micromolar Selenium treated or control PC3 or PAIII
prostate cancer cell lines as described previously[47]. In
brief, ten micrograms of total protein were run on pre-cast
12% reducing SDS PAGE gels (Bio-Rad Labs, Hurcules,
CA) and transferred to PVDF membranes. After blocking
with caseine blocking buffer (Bio-Rad Labs, Hurcules, CA)
the PVDF membranes were incubated with either anti-
RXR-alpha or anti-IGFBP-3 antibodies (Santa Cruz Bio-
technology, Santa Cruz, CA) at 200 µg/ml dilutions,
washed, and incubated with anti-rabbit secondary anti-
body (2 µg/ml) and developed with ECL Chemilumines-
cence (cat. RPN2108, Amersham Biosciences, Piscataway,
New Jersey). Immunoprecipitations were carried out
using 200 microgram samples of total cellular protein,
which after preclearing with protein A agarose beads was
sequentially incubated with either anti-RXR-alpha (1 µg/
ml) or anti-IGFBP-3 (1 µg/ml) antibodies, washed, incu-
bated with anti-rabbit protein A agarose beads, washed,
and the protein pellet western blotted with the compli-
mentary antibody (anti-IGFBP-3 or anti-RXR-alpha,
respectively), and developed with ECL
Chemiluminescence.
Tissue microarray production, immunohistochemistry, and 
analysis
After expedited institutional review board approval nor-
mal prostate tissues and prostate cancer samples were
obtained from de-identified discarded patient specimens.
The formalin-fixed paraffin embedded specimens were
prepared as 5 micron sections. Tissue microarrays were
prepared from donor tissue blocks as 0.6 mm cores in 12BMC Genomics 2004, 5:58 http://www.biomedcentral.com/1471-2164/5/58
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(4 × 4) or (5 × 5) grids with between 192 to 300 samples
and used in the preparation of 5 micron sections. Immu-
nohistochemistry was performed using primary rabbit
polyclonal antibodies to the insulin-like growth factor
binding protein 3 (IGFBP3, 1:300, Santa Cruz Biotechnol-
ogy, Santa Cruz, CA), or retinoic-X-receptor alpha (RXR-
alpha, 1:800, Santa Cruz Biotechnology, Santa Cruz, CA)
using methods previously described [48,49]. In brief,
endogenous peroxidase from deparaffinized sections were
blocked with Methanol/Acetic acid, and after treatment
with blocking serum (ABC kit, Pierce Biotechnology,
Rockford, IL) samples were incubated for 30 minutes with
either anti-IGFBP3 (1:300) or anti-RXRalpha (1:600). Sec-
tions were subsequently washed, and incubated with anti-
rabbitt secondary antibody conjugated to horseradish per-
oxidase and counterstained with Mayers hematoxalin.
Antigen retrieval (90 C waterbath for 10 minutes) was
used for RXRalpha. Positive controls for each antibody
included nuclear staining in Sertoli cells [50] and lym-
phocytes[51]. Positive staining was recorded and scored
on a 0–2 scale (0 = no staining, 1 = staining that does not
obscure the hematoxalyn counterstain, 2 = staining that
obscures the hematoxalyn counterstain). Evidence of pos-
itive staining was recorded as presence of staining (yes/
no) or percent of epithelial or basal cells staining (number
of cells staining over total number of cells). Patterns of
staining (nuclear, cytoplasmic, membranous, diffuse
extracellular) were also recorded. All samples were ana-
lyzed and recorded by two separate personnel, including
a trained urologic pathologist (MWD, BM). Statistical
analysis was performed using Chi-squared probability
analysis.
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